1. The biotransformation of arachidonic acid and prostacyclin in the circulation was studied in anaesthetized dogs, using the blood-bathed organ technique.
Introduction
Prostaglandins are important modulators of vascular smooth-muscle tone. PGEs and PGFs have been considered primarily as local hormones producing their effects close to their site of release since they are inactivated in the lungs before reaching the arterial circulation (Ferreira & Vane, 1967; Vane, 1969) . It is now known that blood vessels in uitro generate prostacyclin (PGI3 as the predominant active metabolite of arachidonic acid; prostacyclin, potently prevents platelet aggregation and also induces disaggregation Johnson, Morton, Kinner, Gorman, McGuire, Sun, Whittaker, Bunting, Salmon, Moncada & Vane, 1976) .
In vitro, prostacyclin relaxes arterial smooth muscle from several species and it causes hypotension in rats, rabbits (Armstrong, Lattimer, Moncada & Vane, 1978) and dogs (Armstrong, Chapple, Dusting, Hughes, Moncada & Vane, 1977) . In the dog, prostacyclin dilates all vascular beds so far studied, including coronary (Dusting, Chapple, Hughes, Moncada & Vane, 1978a) , renal (Hill & Moncada, 1978; Bolger, Eisner, Ramwell, Slotkoff & Corey, 1978) , mesenteric and hindlimb (Dusting, Moncada & Vane, 19786) . It also induces vagally mediated reflex bradycardia and vasodilatation which contributes to the fall in blood pressure (Chapple, Dusting, Hughes & Vane, 1978) .
Arachidonic acid similarly causes hypotension and dilates some vascular beds of the dog (Rose, Johnson, Ramwell & Kot, 1974 ; Dusting el al., 1978b), but constricts perfused lobes of dog lung (Wicks, Rose, Johnson, Ramwell & Kot, 1976 ).
Therefore we have investigated the metabolic transformation of arachidonic acid in the circulation of anaesthetized dogs.
Methods
Mongrel dogs of either sex were anaesthetized with thiopentone (25 mg/kg, intravenously) followed by chloralose (60-80 mg/kg, intravenously) and artificially ventilated. Systemic and pulmonary arterial pressures were measured from catheters inserted via a femoral artery and right jugular vein. Other cannulae were inserted into a carotid or femoral artery and jugular vein for withdrawal and replacement of blood.
Arachidonate metabolites were detected by the blood-bathed organ technique (Vane, 1964) by using up to 6 bioassay tissues including rat stomach strip, rat colon and spirally cut strips of rabbit aorta, rabbit coeliac or mesenteric artery and bovine coronary artery, all of which were rendered insensitive to catecholamines and angiotensin 11 by treatment with phenoxybenzamine (0.1 pg/ml), propranolol ( 2 pg/ml) and (Sarl-Iles) angiotensin I1 (0.025 pglml). In some experiments an incubation coil was interposed between the blood supply and bioassay tissues (Ferreira & Vane, 1967) . Arachidonate and prostacyclin were infused into a femoral vein or into the ascending aorta for 7-15 min.
Results

Arachidonate biotransforrnation in passage across the lungs
Intravenous infusion of sodium arachidonate (SCrSOO pg kg-I min-I) reduced both pulmonary and systemic arterial pressures in proportion to the rate of infusion. During arachidonate infusion there was no change in tone of rabbit aorta, but rabbit coeliac artery, rabbit mesentery artery and bovine coronary artery relaxed and rat stomach strip and rat colon, contracted. The effects of intravenous arachidonic acid could be mimicked by prostacyclin (5-40 ng/ml), infused into the blood bathing the bioassay tissues after it left the animal (Fig. I) , or intravenously (0.1-0.5 pg kg-' min-I). PGE,, PGF,, and PGD, had quite different profiles of activity on the bioassay tissues when infused into the bathing blood. Furthermore, when arachidonate (5-10 pglml) was incubated with blood for 0.1-1.0 min before bathing the assay tissues, all tissues contracted; these contractions were mimicked by exogenous thromboxane A, (0. (Fig. 1) .
Inactivation ofprostacyclin in vascular beds
Prostacyclin infused intravenously has to pass through the lungs before assay in femoral arterial blood. Intravenous infusions of prostacyclin (0.1-0.5 pug kg-I min-I) caused similar decreases in blood pressure and relaxations of rabbit coeliac artery and bovine coronary artery as infusions made into the root of the aorta at the same rates. In contrast, the contraction of rat stomach strip induced by intra-aortic infusion of PGE, (0.2 pg kg-I min-I) could only be matched by intravenous infusions at much higher rates (more than 2 pg kg-' min-l). Thus, prostacyclin, unlike PGE,, is not inactivated in passage through the lungs.
Inactivation of prostacyclin in the peripheral circulation was studied by infusing it via a coaxial catheter. Blood for bioassay was withdrawn via this catheter from the ascending aorta. Estimated rates of inactivation of prostacyclin on one complete circulation were 65%, 50% and 45%.
Discussion
In passage across the lungs arachidonate is transformed into a vasodilating prostacyclin-like substance. There was no evidence for significant conversion into other prostaglandins, but when incubated for sufficient time with blood alone, arachidonic acid is transformed into a thromboxane A,-like substance (Mullane, Dusting, Salmon, Moncada & Vane, 1978) . Indomethacin prevents formation of prostacyclin and abolishes the cardiovascular effects of arachidonic acid. Furthermore, the cardiovascular effects of arachidonate are closely mimicked by prostacyclin but not by other bisenoic prostaglandins which are all pulmonary vasconstrictors (Hyman, Spannhake & Kadowitz, 1978) . Therefore, we suggest that the systemic and pulmonary hypotensive effects of arachidonate are attributable to prostacyclin generation.
Prostacyclin is not inactivated by the pulmonary circulation, and only about 50% disappears on crossing peripheral vascular beds. Therefore prostacyclin released from the lungs could have a role in circulatory control. Indeed, Gryglewski, Korbut & Ocetkiewicz (1978) and Moncada, Korbut, Bunting & Vane (1978) have presented evidence that the lungs continuously release prostacyclin into arterial blood and inhibition of this release probably accounts for contraction after indomethacin of bovine coronary artery bathed in arterial blood. Therefore prostacyclin, unlike PGE,, may be a circulating hormone which supplements the vasodilator and antithrombotic effects of prostacyclin generated locally in the walls of the vasculature.
It has previously been suggested that PGE, may be an important local modulator of vascular tone and a deficiency of this substance may be partly responsible for the augmented response to vasoconstrictor stimuli in hypertension (Terragno, Crowshaw, Terragno & McGiff, 1975; Vane & McGiff, 1975) . Prostacyclin is generally a more potent vasodilator than PGE,, and the difference in potency is increased after abolition of endogenous generation by indomethacin or meclofenamate (Dusting et al., 1978a,b ; G. A. Higgs, S. Moncada & J. R. Vane, unpublished work). Not only is prostacyclin, and not PGE,, the predominant cyclo-oxygenase metabolite of arachidonate in blood vessels, but conventional bioassay and chromatographic procedures previously used to identify release of prostaglandin-like substances do not readily distinguish between PGE, and prostacyclin or its stable degradation product (6-0x0-PGFIa; Cottee, Flower, Moncada, Salmon & Vane, 1977) . Clearly, prostacyclin generation should be taken into account when assessing the contribution of prostaglandinlike substances to the regulation of blood vessel tone and blood pressure.
